medigraphic.com
ISSN 1817-5996 (Electronic)

2021, Number 2

<< Back Next >>

Rev Cub de Reu 2021; 23 (2)

Considerations on the association of atherosclerosis and rheumatoid arthritis

Caspi PLM, Peralvo SJA, Peralvo SMF, Peralvo SSP

Language: Spanish
References: 30
Page: 1-13
PDF size: 457.86 Kb.


ABSTRACT

Rheumatoid arthritis and atherosclerosis are two strictly related inflammatory diseases. To show different authors' considerations on the association between atherosclerosis and rheumatoid arthritis. Rheumatoid arthritis ―related inflammation can lead to the onset of atherosclerosis in several ways. It is important to evaluate and monitor rheumatoid arthritis patients to detect the existence of existing traditional risk factors for the appearance of CVD, in order to reduce the impact on the cardiovascular system.


REFERENCES

  1. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-07. DOI: https://doi.org/10.1161/01.cir.0000054612.26458.b2

  2. Edwards CJ, Syddall H, Goswami R, Goswami P, Dennison EM, Arden NK, et al. The autoantibody heumatoid factor may be an Independent risk factor for ischaemic heart disease. Heart. 2007;93(10):1263-7. DOI: https://doi.org/10.1136/hrt.2006.097816

  3. Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular évents in rheumatoid arthritis: lévéls of associations of myocardial infarction and stroke through a systématic review and méta-analysis. Arch Cardiovascular Diseases. 2010;103(4):253-61. DOI: https://doi.org/10.1016/j.acvd.2010.03.007

  4. Mirjafari H, Al-Husain A, Bruce IN. Cardiovascular risk factors in inflammatory arthritis. Current Opinion in Lipidology. 2011;22(4):296-301. DOI: https://doi.org/10.1097/MOL.0b013e3283488c50

  5. Roman MJ, Naqvi TZ, Gardin JM. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: A report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006;19:943-54. DOI: https://doi.org/10.1016/j.echo.2006.04.020

  6. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146(6):483-94.

  7. Kallberg H, Ding B, Padyukov L. Bengtsson C, Rönnelid J. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks alter various exposures to cigarette smoke. Annals of the Rheumatic Diseases. 2011;70(3):508-511.

  8. Pemberton PW, Ahmad Y, Bodill H, Lokko D, Hider SL. Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: A cross-sectional study of their association with accelerated atherosclerosis. BMC Research Notes. 2009;2(1):1-7. DOI: https://doi.org/10.1186/1756-0500-2-83

  9. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year follow-up study of a primary care-based inception cohort. Arthritis and Rheumatism. 2005;52(8):2293-9.

  10. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis -A model of systemic inflammation driving atherosclerosis. Circulation J. 2009;73(6):977-85.

  11. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sciences. 2003;72(25):2877-85.

  12. Marder W, Khalatbari S, Myles JD, Hench R, Yalavarth S. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheumatic Diseases. 2011;70(9):1550-5. DOI: https://doi.org/10.1136/ard.2010.148031

  13. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL. Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatology. 2010;37(3):529-35.

  14. Ahmed MS, Youssef M, Mosaad YM. Anti-bodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clinical Rheumatology. 2010;29(11):1237-43. DOI: https://doi.org/10.1007/s10067-010-1436-0

  15. Pansuria M, Xi H, Li L, Yang XF, Wang H. Insulin resistance, metabolic stress and atherosclerosis. Frontiers in Bioscience. 2012;4:916-31.

  16. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England J Medicine. 2005;352(11):1092-102.

  17. Alacqua M, Trifiro G, Cavagna L, Caporali, R, Montecucco CM. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Care and Research. 2008;59(4):568-74.

  18. Van Der Linden MW, Van Der Bij S, Welsing P, Kuipers EJ, Herings RMC. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases. 2009;68(5):668-73. DOI: https://doi.org/10.1136/ard.2007.087254

  19. Morrison E, Capell HA. Corticosteroids in the management of early and established rheumatoid disease. Rheumatology. 2006;45(9):1058-61.

  20. Makinen H, Kautiainen H, Hannonen P, Möttönen T, Leirisalo-Repo M. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. Journal of Rheumatology. 2007;34(2):316-21.

  21. Landewe RBM, Van Den Borne BE, Breedveld FC, Dijkmans BAC. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. The Lancet. 2000;355(9215):1616-7.

  22. Tabit CE, Holbrook M, Shenouda SM, Dohadwala MM, Widlansky ME. Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. Vascular Medicine. 2012;17(2):101-07.

  23. Szekanecz Z, Kerekes G, Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nature Reviews Rheumatology. 2009;5(12):677-84.

  24. Da'ien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Annals of the Rheumatic Diseases. 2012;71(6):862-8. DOI: https://doi.org/10.1136/annrheumdis-2011-201148

  25. Gonzalez MA, Gonzalez C, Vazquez TR, Miranda JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-a therapy: annals of the New York Academy of Sciences. Annals of the New York Academy of Sciences. 2010:1193:153-9. DOI: https://doi.org/10.1111/j.1749-6632.2009.05287.x

  26. Gonzalez MA, Garcia MT, Gonzalez C, Miranda-Filloy JA, Vazquez-Rodriguez TR. Anti-TNF-a therapy modulates resistin in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 2008;26(2):311-6.

  27. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R. Anti-tumor necrosis factor a treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106(17):2184-7.

  28. Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmunity Reviews. 2010;9(12):835-9. DOI: https://doi.org/10.1016/j.autrev.2010.07.018

  29. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-a, rheumatoid arthritis, and heart failure: A rheumatological dilemma. Autoimmunity Reviews. 2005;4(3):53-161.

  30. Kerekes G, Soltesz P, Der H, Veres K, Szabo Z. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clinical Rheumatology. 2009;28(6):705-10. DOI: https://doi.org/10.1007/s10067-009-1095-1




2020     |     www.medigraphic.com